Design of a Bayesian adaptive phase 2 proof‐of‐concept trial for BAN2401, a putative disease‐modifying monoclonal antibody for the treatment of Alzheimer's disease
Research article (Alzheimer s & Dementia Translational Research & Clinical Interventions, 2016) · cited 87× · AI/ML